Insights into the diagnosis and treatment of lysosomal storage diseases

Archives of Neurology

Volumn 60, Issue 3, 2003, Pages 322-328

  Wenger, David A ^a   Coppola, Stephanie ^a   Liu, Shu Ling ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MANNOSIDASE;

ASPARTYLGLYCOSAMINURIA; BETA MANNOSIDOSIS; BRAIN TISSUE; DEMYELINATING DISEASE; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; FARBER DISEASE; FUCOSIDOSIS; GALACTOSIALIDOSIS; GAUCHER DISEASE; GENETIC DISORDER; GLOBOID CELL LEUKODYSTROPHY; GLYCOGEN STORAGE DISEASE TYPE 2; GM1 GANGLIOSIDOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MANNOSIDOSIS; METABOLITE; METACHROMATIC LEUKODYSTROPHY; MUCOLIPIDOSIS TYPE 2; MUCOLIPIDOSIS TYPE 4; MULTIPLE SULFATASE DEFICIENCY; NEURONAL CEROID LIPOFUSCINOSIS; NIEMANN PICK DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SANDHOFF DISEASE; SANFILIPPO SYNDROME; SCHEIE SYNDROME; SIALIC ACID STORAGE DISEASE; SIALIDOSIS; SYMPTOM; TAY SACHS DISEASE; WOLMAN DISEASE;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; LYSOSOMAL STORAGE DISEASES;

EID: 0037338339     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.3.322     Document Type: Review

References (26)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.
2. Wenger DA, Williams C. Screening for lysosomal disorders. In: Hommes FA, ed. Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual. New York, NY: Wiley-Liss; 1991:587-617.
3. Kotagal S, Wenger DA, Alcala H, Gomez C, Horenstein S. AB variant GM2 gangliosidosis: cerebrospinal fluid and neuropathological characteristics. Neurology. 1986;36:438-440.
4. Gieselmahn V, Polten A, Kreysing J, Von Figura K. Arylsulphatase A pseudodeficiency: loss of a polyadenylation signal and N-glycosylation site. ProcNatlAcad Sci U S A. 1989;86:9436-9440.
5. Gieselmann V, Fluharty AL, Tonnesen T, Von Figura K. Mutations in the arylsulfatase A pseudodeficiency allele causing metachromatic leukodystrophy. Am J Hum Genet. 1991;49:407-413.
6. Vanier MT, Wenger DA, Comly ME, Rousson R, Brady RO, Pentchev PG. Niemann-Pick group C: clinical variability and diagnosis based on defective cholesterol esterification. Clin Genet 1988;33:331-348.
7. Millat G, Marcais C, Tomasetto C, et al. Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteinerich luminal loop. Am J Hum Genet. 2001;68:1373-1385.
8. Millat G, Chikh K, Naureckiene S, et al. Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am J Hum Genet. 2001;69:1013-1021.
9. Wenger DA, Rafi MA, Luzi P, Datto J, Costantino-Ceccarini E, Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab. 2000;70:1-9.
10. Hua CT, Hopwood JJ, Carlsson SR, Harris RJ, Meikle PJ. Evaluation of the lysosome-associated membrane protein LAMP-2 as a marker for lysosomal storage disorders. Clin Chem. 1998;44:2094-2102.
11. Chang MHY, Bindloss CA, Grabowski GA, et al. Saposins A, B, C, and D in plasma of patients with lysosomal storage disorders. Clin Chem. 2000;46:167-174.
12. Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem. 2001;47:2098-2102.
13. Clarke S. Tandem mass spectrometry: the tool of choice for diagnosing inborn errors of metabolism? Br J Biomed Sci. 2002;59:42-46.
14. Ringden O, Groth CG, Erikson A, Granqvist S, Mansson JE, Sparrelid E. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation. 1995;59:864-870.
15. Vellodi A, Young EP, Cooper A, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience in two British centres. Arch Dis Child. 1997;76:92-99.
16. Krivit W, Aubourg P, Shapiro E, Peters C. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr Opin Hematol. 1999;6:377-382.
17. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 1998;12:115-133.
18. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16.
19. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344:182-188.
20. Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-2749.
21. Sundaram KS, Lev M. Inhibition of cerebroside synthesis in the brains of mice treated with L-cycloserine. J Lipid Res. 1985;26:473-477.
22. Andersson U, Butters TD, Dwek RA, Platt FM. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol. 2000;59:821-829.
23. Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1999;96:6388-6393.
24. Ghodsi A, Stein C, Derksen T, Yang G, Anderson RD, Davidson BL. Extensive β-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum Gene Ther. 1998;9:2331-2340.
25. Bosch A, Perret E, Desmaris N, Trono D, Heard JM. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther. 2000;11:1139-1150.
26. Gage FH. Mammalian neural stem cells. Science. 2000;287:1433-1438.